Home › Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment
 

Keywords :   


Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment

2013-09-09 14:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck is seeking FDA approval of corifollitropin alfa for Controlled Ovarian Stimulation (COS) in women participating in assisted reproductive technology. Language: English Contact: MerckMedia:Pam Eisele, 908-423-5042orTina Grasso, 267-893-9783orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: application treatment drug acceptance

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Atlantic Tropical Weather Outlook
29.06Eastern North Pacific Tropical Weather Outlook
28.06What we learned from IT expert at Post Office inquiry
28.06M&S to launch clothing repairs service
28.06Tropical Depression Two Graphics
28.06Tropical Depression Two Public Advisory Number 1
28.06Summary for Tropical Depression Two (AT2/AL022024)
28.06Tropical Depression Two Forecast Advisory Number 1
More »